Aggregation and deposition of amyloid-β (Aβ) in the brain is the main pathological change of Alzheimer’s disease (AD). Decreased Aβ42 in the cerebrospinal fluid has been confirmed as a biomarker of AD; however, the relationship between plasma Aβ and cognitive impairment is currently unclear.
Objective:
The aim was to explore the relationship between plasma Aβ and cognitive impairment in a cross-sectional study.
Methods:
A total of 1,314 subjects (age above 40) from a village in the suburbs of Xi’an, China were enrolled between October 8, 2014 and March 30, 2015. A validated Chinese version of the Mini-Mental State Examination and neuropsychological battery were used to assess cognition. Levels of plasma Aβ42 and Aβ40 were tested using commercial enzyme-linked immunosorbent assay. Relationship of plasma Aβ and cognitive impairment was analyzed using logistic regression analysis.
Results:
Of the enrolled subjects, 1,180 (89.80%) had normal cognition, 85 (6.47%) had possible cognitive impairment and 49 (3.73%) had probable cognitive impairment. Logistic regression analysis showed that the Aβ42/Aβ40 ratio (OR = 4.042, 95% CI: 1.248–11.098, p = 0.012) and plasma Aβ42 (OR = 1.036, 95% CI: 1.003–1.071, p = 0.031) was higher in the possible cognitive impairment than that in the normal cognition group. Furthermore, the plasma Aβ42/Aβ40 ratio was higher in the possible cognitive impairment group than that in the probable cognitive impairment group (OR = 0.029, 95% CI: 0.002–0.450, p = 0.011).
Conclusions:
Levels of plasma Aβ42 and Aβ42/Aβ40 ratio were elevated in patients with possible cognitive impairment, indicating that plasma Aβ42 and Aβ42/Aβ40 ratio increases may be more pronounced in early stage of cognitive impairment.
BondiMW, EdmondsEC, SalmonDP (2017) Alzheimer’s disease: Past, present, and future. J Int Neuropsychol Soc23, 818–831.
2.
QuerfurthHW, LaFerlaFM (2010) Alzheimer’s disease. N Engl J Med362, 329–344.
3.
Area-GomezE, SchonEA (2017) On the pathogenesis of Alzheimer’s disease: The MAM Hypothesis. FASEB J31, 864–867.
4.
MayeuxR, HonigLS, TangMX, ManlyJ, SternY, SchupfN, MehtaPD (2003) Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: Relation to age, mortality, and risk. Neurology61, 1185–1190.
5.
GowertNS, DonnerL, ChatterjeeM, EiseleYS, TowhidST, MunzerP, WalkerB, OgorekI, BorstO, GrandochM, SchallerM, FischerJW, GawazM, WeggenS, LangF, JuckerM, ElversM (2014) Blood platelets in the progression of Alzheimer’s disease. PLoS One9, 90523.
6.
DeMattosRB, BalesKR, ParsadanianM, O’DellMA, FossEM, PaulSM, HoltzmanDM (2002) Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer’s disease. J Neurochem81, 229–236.
7.
GiedraitisV, SundelofJ, IrizarryMC, GarevikN, HymanBT, WahlundLO, IngelssonM, LannfeltL (2007) The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer’s disease. Neurosci Lett427, 127–131.
8.
MatsuokaY, SaitoM, LaFrancoisJ, SaitoM, GaynorK, OlmV, WangL, CaseyE, LuY, ShiratoriC, LemereC, DuffK (2003) Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci23, 29–33.
9.
BoadaM, AnayaF, OrtizP, OlazaranJ, Shua-HaimJR, ObisesanTO, HernandezI, MunozJ, BuendiaM, AlegretM, LafuenteA, TarragaL, NunezL, TorresM, GrifolsJR, FerrerI, LopezOL, PaezA (2017) Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-beta concentrations and cognition outcomes in Alzheimer’s disease patients: A multicenter, randomized, controlled clinical trial. J Alzheimers Dis56, 129–143.
10.
RobertsKF, ElbertDL, KastenTP, PattersonBW, SigurdsonWC, ConnorsRE, OvodV, MunsellLY, MawuenyegaKG, Miller-ThomasMM, MoranCJ, CrossDT3rd, DerdeynCP, BatemanRJ (2014) Amyloid-beta efflux from the central nervous system into the plasma. Ann Neurol76, 837–844.
11.
DeaneR, Du YanS, SubmamaryanRK, LaRueB, JovanovicS, HoggE, WelchD, MannessL, LinC, YuJ, ZhuH, GhisoJ, FrangioneB, SternA, SchmidtAM, ArmstrongDL, ArnoldB, LiliensiekB, NawrothP, HofmanF, KindyM, SternD, ZlokovicB (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med9, 907–913.
12.
DeaneR, SagareA, ZlokovicBV (2008) The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer’s disease. Curr Pharm Des14, 1601–1605.
13.
SagareAP, WinklerEA, BellRD, DeaneR, ZlokovicBV (2011) From the liver to the blood-brain barrier: An interconnected system regulating brain amyloid-beta levels. J Neurosci Res89, 967–968.
ScheunerD, EckmanC, JensenM, SongX, CitronM, SuzukiN, BirdTD, HardyJ, HuttonM, KukullW, LarsonE, Levy-LahadE, ViitanenM, PeskindE, PoorkajP, SchellenbergG, TanziR, WascoW, LannfeltL, SelkoeD, YounkinS (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med2, 864–870.
MehtaPD, PirttilaT, PatrickBA, BarshatzkyM, MehtaSP (2001) Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett304, 102–106.
18.
LewczukP, KornhuberJ, VanmechelenE, PetersO, HeuserI, MaierW, JessenF, BurgerK, HampelH, FrolichL, HennF, FalkaiP, RutherE, JahnH, LuckhausC, PerneczkyR, SchmidtkeK, SchroderJ, KesslerH, PantelJ, GertzHJ, VandersticheleH, de MeyerG, ShapiroF, WolfS, BiblM, WiltfangJ (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: A multicenter study with multiplexing. Exp Neurol223, 366–370.
19.
LuiJK, LawsSM, LiQX, VillemagneVL, AmesD, BrownB, BushAI, De RuyckK, DromeyJ, EllisKA, FauxNG, FosterJ, FowlerC, GuptaV, HudsonP, LaughtonK, MastersCL, PertileK, RembachA, RimajovaM, RodriguesM, RoweCC, RumbleR, SzoekeC, TaddeiK, TaddeiT, TrounsonB, WardV, MartinsRN, AIBL Research Group (2010) Plasma amyloid-beta as a biomarker in Alzheimer’s disease: The AIBL study of aging. J Alzheimers Dis20, 1233–1242.
20.
BlennowK, De MeyerG, HanssonO, MinthonL, WallinA, ZetterbergH, LewczukP, VandersticheleH, VanmechelenE, KornhuberJ, WiltfangJ, GroupKN-S, HeuserI, MaierW, LuckhausC, RutherE, HullM, JahnH, GertzHJ, FrolichL, HampelH, PernetzkiR (2009) Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer’s disease: a multicenter assessment. J Nutr Health Aging13, 205–208.
21.
YuanJ, ZhangZ, WenH, HongX, HongZ, QuQ, TangM, WuJ, XuQ, LiH, CummingsJL (2016) Incidence of dementia and subtypes: A cohort study in four regions in China. Alzheimers Dement12, 262–271.
22.
KatzmanR, ZhangMY, Ouang YaQ, WangZY, LiuWT, YuE, WongSC, SalmonDP, GrantI (1988) A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol41, 971–978.
23.
BohmM, SchumacherH, LeongD, ManciaG, UngerT, SchmiederR, CustodisF, DienerHC, LaufsU, LonnE, SliwaK, TeoK, FagardR, RedonJ, SleightP, AndersonC, O’DonnellM, YusufS (2015) Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension65, 651–661.
24.
ShulmanKI (2000) Clock-drawing: Is it the ideal cognitive screening test?. Int J Geriatr Psychiatry15, 548–561.
25.
FuldPA, MasurDM, BlauAD, CrystalH, AronsonMK (1990) Object-memory evaluation for prospective detection of dementia in normal functioning elderly: Predictive and normative data. J Clin Exp Neuropsychol12, 520–528.
26.
HenryJD, CrawfordJR, PhillipsLH (2004) Verbal fluency performance in dementia of the Alzheimer’s type: A meta-analysis. Neuropsychologia42, 1212–1222.
27.
JohansonAM, GustafsonL, RisbergJ (1986) Behoral observations during performance of the WAIS Block Design Test related to abnormalities of regional cerebral blood flow in organic dementia. J Clin Exp Neuropsychol8, 201–209.
28.
SimardM, van ReekumR (1999) Memory assessment in studies of cognition-enhancing drugs for Alzheimer’s disease. Drugs Aging14, 197–230.
29.
Association AP
(2013) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.
30.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
31.
RomanGC, TatemichiTK, ErkinjunttiT, CummingsJL, MasdeuJC, GarciaJH, AmaducciL, OrgogozoJM, BrunA, HofmanA, .
(1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology43, 250–260.
LiuLS, Writing Group of Chinese Guidelines for the Management of H
(2011) [2010 Chinese guidelines for the management of hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi39, 579–615.
36.
ZhaoY, XuG, WuW, YiX (2015) Type 2 diabetes mellitus- disease, diagnosis and treatment. J Diabetes Metab533.
37.
YewKS, ChengEM (2015) Diagnosis of acute stroke. Am Fam Physician91, 528–536.
38.
SimmonsBB, CirignanoB, GadegbekuAB (2012) Transient ischemic attack: Part I. Diagnosis and evaluation. Am Fam Physician86, 521–526.
39.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackJr CR, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
40.
OvodV, RamseyKN, MawuenyegaKG, BollingerJG, HicksT, SchneiderT, SullivanM, PaumierK, HoltzmanDM, MorrisJC, BenzingerT, FaganAM, PattersonBW, BatemanRJ (2017) Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement13, 841–849.
LopezOL, KullerLH, MehtaPD, BeckerJT, GachHM, SweetRA, ChangYF, TracyR, DeKoskyST (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology70, 1664–1671.
43.
LocascioJJ, FukumotoH, YapL, BottiglieriT, GrowdonJH, HymanBT, IrizarryMC (2008) Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol65, 776–785.
44.
FaganAM, MintunMA, MachRH, LeeSY, DenceCS, ShahAR, LaRossaGN, SpinnerML, KlunkWE, MathisCA, DeKoskyST, MorrisJC, HoltzmanDM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol59, 512–519.
VerbeekMM, EikelenboomP, de WaalRM (1997) Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer disease. J Neuropathol Exp Neurol56, 751–761.
47.
RoebenB, MaetzlerW, VanmechelenE, SchulteC, HeinzelS, StellosK, GodauJ, HuberH, BrockmannK, WursterI, GaenslenA, GrunerE, NieblerR, EschweilerGW, BergD, TREND study team (2016) Association of plasma Abeta40 peptides, but not Abeta42, with coronary artery disease and diabetes mellitus. J Alzheimers Dis52, 161–169.
48.
ParkL, ZhouP, KoizumiK, El JamalS, PrevitiML, Van NostrandWE, CarlsonG, IadecolaC (2013) Brain and circulating levels of Abeta1-40 differentially contribute to vasomotor dysfunction in the mouse brain. Stroke44, 198–204.
49.
GomisM, SobrinoT, OisA, MillanM, Rodriguez-CampelloA, Perez de la OssaN, Rodriguez-GonzalezR, Jimenez-CondeJ, Cuadrado-GodiaE, RoquerJ, DavalosA (2009) Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype. Stroke40, 3197–3201.
